FDA upping drug inspections in China; Mylan sues Celgene for blocking generics;

@FiercePharma: Trending on FierceVaccines: GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. More | Follow @FiercePharma

@TracyStaton: Still best-read FiercePharma: It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. Story | Follow @TracyStaton

@EricPFierce: RT: Last year, my sister died, and I learned firsthand about life sciences' limits. Article from FierceMedicalDevices | Follow @EricPFierce

@CarlyHFierce: Amgen, GSK part on fast-selling Prolia, mostly. More | Follow @CarlyHFierce

> The FDA is increasing its inspections of drugs in China, the top official there testified Thursday. Story

> Mylan ($MYL) has sued Celgene ($CELG) for its efforts to keep generics of Revlimid and Thalomid off the market. Report

> Arkansas Attorney General Dustin McDaniel says he's asking the state Supreme Court to reconsider its decision to toss out a $1.2 billion judgment against Johnson & Johnson ($JNJ) over the marketing of the antipsychotic drug Risperdal. Story

> Vermont is requiring doctors to conduct a risk assessment before prescribing Zogenix's ($ZGNX) controversial new high-powered painkiller Zohydro. More

> Pharmaceutical companies paid healthcare professionals in the U.K. a total of £38.5 million last year for speaking at healthcare conferences, down slightly from the year before. Story

Medical Device News

@FierceMedDev: J&J gets a mixed verdict in a trial alleging it sold faulty vaginal mesh implants. More | Follow @FierceMedDev

@MarkHFierce: ICYMI: Biotronik may have a relatively small U.S. mkt share, but it is working hard to compete here. Story | Follow @MarkHFierce

@MichaelGFierce: The year in nanotech drug delivery. Special report | Follow @MichaelGFierce

@EmilyWFierce: Adhesive medical sensors with origami-like wires could flex and bend with the skin, say researchers at Northwestern University. News | Follow @EmilyWFierce

> RefleXion raises $11.6M in Series A funding round. More

> Holaira brings in $42M Series D to test COPD lung denervation treatment tool. Article

> Vapotherm seals $24M financing round, elects new board member. Story

Biotech News

@FierceBiotech: For those of you just waking up and getting to work in the U.S., here's our second issue of EuroBiotech: Read | Follow @FierceBiotech

@JohnCFierce: Amgen down 1.7%. I'm going to start calling Amgen a pharma co. If it walks like a duck... | Follow @JohnCFierce

@DamianFierce: Amgen: T-Vec hits on durable response but misses on OS, its secondary endpoint. Release | Follow @DamianFierce

@EmilyMFierce: The current environment for cancer care in Europe: Infographic via Janssen | Follow @EmilyMFierce

> AbbVie gets out of the way as the EU prepares for trial transparency. More

> Merck and Ferring team up on anti-bleeding drug for the developing world. News

> GTx's CEO finds the door as the company moves on from a PhIII failure. Article

And Finally... FDA Commissioner Margaret Hamburg expects her agency's proposal on e-cigarette regulation to be ready for release "very soon." More

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.